Ways to Give: Join a Steps Against Melanoma Walk
Steps Against Melanoma is AIM at Melanoma’s Walk & Fun Run program. These Walks are the largest public events AIM…
Ways to Give: Join a Steps Against Melanoma Walk
Steps Against Melanoma is AIM at Melanoma’s Walk & Fun Run program. These Walks are the largest public events AIM…
,
Newly Published Trial Data for Melanoma
…immune cells turn off instead of attacking the growing tumor. When immune cells encounter melanoma cells, they may express a…
,
FAQ and Update on AIM at Melanoma’s International Melanoma Tissue Bank Consortium
…University (Chicago, IL). Finally, the suspected melanoma must be large enough to bank. So ironically, it is people likely unfamiliar…
,
President’s Letter | March 2021
…last month’s special edition of In Plain English—COVID-19, the vaccines, and melanoma: What do melanoma patients and their families need…
,
Interview with Dr. Zeynep Eroglu, Medical Oncologist, Moffitt Cancer Center
…and other skin cancers, along with development of personalized treatment strategies and biomarkers for patients with melanoma. Dr. Eroglu is…
,
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag
…of melanoma has been increasing steadily for the last 30 years. In the United States, 106,110 new diagnoses of melanoma…
,
Melanoma By The State: Tennessee
…as part of a video conference panel on living with melanoma, and more recently to raise money for melanoma research.…
,
Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag , for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1%
…potentiate anti-tumor immune activity. Bristol Myers Squibb is evaluating relatlimab, its LAG-3-blocking antibody, in clinical trials in combination with other…
,
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
…(DMFS), progression-free survival on next-line therapy (PFS2), and safety endpoints. About Melanoma Melanoma is a form of skin cancer characterized…
,
,
President’s Letter | May 2021
…melanoma. May is the perfect time to remind everyone about using sunscreen, seeking shade, making their annual skin check appointments,…
,
Recent Posts
Mar. 26, 2026
Wade Watson, Stage III Melanoma Survivor: A Marathon, Not a Sprint
Mar. 03, 2026
Cancer is More Than a Diagnosis: Mind, Meaning, and Healing
Feb. 19, 2026
Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN®
Feb. 05, 2026
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
Jan. 23, 2026